Selective 5-HT$_{1A}$-R-agonist Repinotan Prevents Remifentanil-induced Ventilatory Depression and Prolongs Antinociception

Ulf Guenther, M.D.,* Nils U. Theuerkauf, M.D.,* Daniel Huse, M.D.,† Michael F. Boettcher, M.D.,‡ Georg Wensing, M.D., Ph.D.,§ Christian Putensen, M.D., Ph.D.,¶ Andreas Hoeft, M.D., Ph.D.#

ABSTRACT

Background: 5-HT$_{1A}$-R-agonist repinotan was shown to counteract a morphine-induced ventilatory depression but had pronociceptive effects at small doses (0.2 μg/kg). It remained to be clarified (1) whether a moderate dose of repinotan, sufficient to stimulate spontaneous breathing, impairs antinociception if plasma concentration decreases over time, and (2) whether moderate doses prevent ventilatory depression if given before the opioid.

Methods: A dose–response curve of the repinotan effects on spontaneous minute ventilation during continuous remifentanil infusion in anesthetized rats was established to identify moderate doses: (1) tail-flick reflex latencies to assess nociception were recorded until 60 min after cessation of a continuous remifentanil infusion with or without a concomitant moderate repinotan dose (10 μg/kg), and (2) remifentanil boluses (2.5 μg/kg) were given after repinotan (10 and 20 μg/kg).

Results: (1) Remifentanil-induced antinociception lasted only 5 min after infusion was stopped (tail-flick reflex latencies; median [interquartile range], 97 [54–100]% of maximum possible effect; P = 0.034), but was extended by repinotan (10 μg/kg) to 30 min (tail-flick reflex latencies, 100 [75–100]% of maximum possible effect; P = 0.031). Repinotan (10 μg/kg) alone did not have any significant antino- ciceptive effect. (2) The ventilatory depression by remifentanil boluses (2.5 μg/kg; minute ventilation, −65 [−81 to −56]%; P = 0.031, n = 5) was blunted by repinotan (20 μg/kg; minute ventilation, −24 [−53 to 13]%; P = 0.313, compared with the pretreatment level).

Conclusions: Repinotan prevented remifentanil-induced ventilatory depression in spontaneously breathing, anesthetized rats. Although repinotan did not depress nociception itself, it prolonged the profound antinociception after discontinuation of remifentanil infusion.

What We Already Know about This Topic
- Opioid-induced respiratory depression is a dose-limiting side effect in the safe clinical use of opioids.
- The serotonergic receptor type 1A agonist repinotan antagonizes morphine-induced respiratory depression but has a pronociceptive effect at low doses.

What This Article Tells Us That Is New
- Repinotan prevented respiratory depression after bolus injection of remifentanil and prolonged, rather than antagonized, antinociception in spontaneously breathing anesthetized rats.
- Serotonergic receptor type 1A agonists warrant additional study as opioid adjuncts for their ventilatory effects.

VENTILATORY depression is a major devastating adverse event of opioid-based pain therapy and brief opioid-treated painful procedures in the clinic.1,2 The selective, full 5-HT$_{1A}$-R-agonist repinotan3,4 has been shown to counteract morphine-induced ventilatory depression in spontaneously breathing rats.3 Unlike other 5-HT$_{1A}$-R agonists, repinotan is approved for intravenous use in humans and has undergone a series of clinical phase II trials into neuroprotection after traumatic brain injury and stroke.6–9 Nociception, assessed with a tail-flick reflex, was shown to be enhanced with very small doses (0.2 μg/kg), indicating pronociception.5 A moderate dose of repinotan (20 μg/kg), sufficient to stimulate spontaneous breathing, produced a nonsignificant trend toward antinociception; higher doses (200 μg/kg) reached statistical significance. It was not investigated whether moderate repinotan doses have pronociceptive effects with plasma concentrations decreasing over time.

The ultrashort-acting opioid remifentanil is used with bolus injections in a growing number of brief, painful pro-
currencies, such as dilatation and sharp curettage, dentistry, tonsillectomy, adenectomy, bronchoscopy, and gastroscopy, with antinociception quickly wearing off after the procedure. Interestingly, the selective 5-HT1A-R-agonist F13640 was shown to reduce postoperative analgesic requirements after remifentanil in rats.12 The question arises of whether repinotan at moderate doses sufficient to stimulate spontaneous breathing also contributes to opioid analgesia. In addition, it was not investigated if repinotan prevents ventilatory depression if given before opioid administration.

This study was carried out (1) to establish a dose–response curve of repinotan on the counteraction of remifentanil-induced ventilatory depression, (2) to determine the effects of a moderate repinotan dose (10 μg/kg) on nociception after discontinuation of a remifentanil infusion, and (3) to verify if repinotan prevents ventilatory depression if given before remifentanil bolus injections in spontaneously breathing, anesthetized rats.

Materials and Methods

Animals

This study was performed with approval from the local Institutional Animal Review Board for animal research (Cologne, Germany) and in accordance with the “Guide for the Care and Use of Laboratory Animals.”** The experimental setup has been described in detail elsewhere.5 In brief, 50 male Sprague-Dawley rats (median weight, 284 g; range, 208–370 g; Charles River GmbH, Sulzfeld, Germany) were deeply anesthetized with a single intraperitoneal injection of sodium-pentobarbitone (60 mg/kg) and placed supine on a heating pad to maintain rectal temperature constantly at 37° ± 0.5°C. The right inguinal artery and vein were cannulated via a small surgical incision for intravenous application of study drugs and continuous monitoring of heart rate (HR) and mean arterial blood pressure (MAP). A tracheostomy was performed, and anesthesia was maintained with sevoflurane, as soon as animals produced signs of subsiding barbiturate effect. Anesthesia was established during continuous remifentanil infusion (GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany). NaCl 0.9% (Braun, Melsungen, Germany) were given as a control for fluid balance, or the standard 5-HT1A-R-agonist 8-OH-DPAT ([+]-8-Hydroxy-2-(di-N-propylamino)-tetralin; Tocris, Bristol, United Kingdom), or NaCl 0.9% (Braun, Melsungen, Germany) were given as a control for fluid balance, or the standard 5-HT1A-R-agonist 8-OH-DPAT ([+]-8-Hydroxy-2-(di-N-propylamino)-tetralin; Tocris, Bristol, United Kingdom), or NaCl 0.9% (Braun, Melsungen, Germany) were given as a control for fluid balance, or the standard 5-HT1A-R-agonist 8-OH-DPAT ([+]-8-Hydroxy-2-(di-N-propylamino)-tetralin; Tocris, Bristol, United Kingdom). Anesthesia was maintained with sevoflurane, as soon as animals produced signs of subsiding barbiturate effect. Anesthesia was established during continuous remifentanil infusion (GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany).

Drug Application Protocols

A schematic overview of the drug application protocol is given in figure 1.

- Nociception. Nociception was assessed with a tail-flick reflex. Before the first tail-flick reflex was taken, at least 30 min was allowed for acclimation to sevoflurane, except for the group without continuous remifentanil infusion, which had an additional 60 min (see fig. 1). The latency of the tail-flick reflex response (tail-flick reflex latency [TFL]), evoked by a 100-W light beam source mounted 15 mm over the base of the tail, was recorded with a strain gauge attached to the tail. The TFL was determined as the distance between the spike artifact evoked by the power-on of the heating source and the tail-flick response detected by the strain gauge.

- Drug Application Protocols

A schematic overview of the drug application protocol is given in figure 1.

- Dose–response curves on MV of increasing doses of either repinotan (R-(-)-2-[4-[(chroman-2-ylmethyl)-amino]-butyl]-1,1-dioxo-benzo[di]isothiazolone-hydro-chloride; Bayer Healthcare AG, Wuppertal, Germany), or the standard 5-HT1A-R-agonist 8-OH-DPAT ([+]-8-Hydroxy-2-(di-N-propylamino)-tetralin; Tocris, Bristol, United Kingdom), or NaCl 0.9% (Braun, Melsungen, Germany) were established during continuous remifentanil infusion (GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany) to delineate moderate doses.

- After the identification of 10 μg/kg repinotan as a moderate dose, the effects of such a single dose on TFL after discontinuation of an 80-min infusion of remifentanil, repinotan alone, and remifentanil alone were assessed to 60 min after discontinuation of the continuous remifentanil infusion. The effects of moderate doses of repinotan (10 and 20 μg/kg) on spontaneous breathing given before bolus injections of remifentanil were measured.

- Repinotan and Continuous Remifentanil Infusion. The remifentanil infusion rate was set to achieve a 50% reduction in respiratory frequency. Thereafter, repinotan was injected...
intravenously every 15 min, with doses ranging from 0.1 µg/kg to 100 µg/kg (n = 6, fig. 1, A1). For comparison, the standard 5-HT1A-R-agonist 8-OH-DPAT was given at doses of 0.1 to 10 µg/kg (n = 6, fig. 1, A2). NaCl 0.9% injections served as controls. TFL were recorded before the start of remifentanil infusion (and taken as pretreatment level), 5 min thereafter, and at the end of the remifentanil infusion. We did not perform TFL measurements between 5-HT1A-R-agonist administrations because the tail-flick reflex was always abolished with the onset of remifentanil and remained absent throughout preliminary experiments as long as remifentanil was infused continuously. After completion of the remifentanil and NaCl 0.9% series, a single bolus of repinotan (10 µg/kg, n = 6, fig. 1, A4) was given, and TFLs were determined at 5, 15, 30, 45, and 60 min thereafter. This was done to determine the time profile of the nociceptive effects of repinotan and remifentanil after 80 min of continuous remifentanil infusion. In an additional series, repinotan (10 µg/kg) was given without previous remifentanil infusion (n = 7, fig. 1, A5). All experiments were performed by one of the coauthors (D.H.) and a technical assistant. For technical reasons, they were not blinded to treatment groups. Both were unaware of the drug effects and did not participate in the data analysis.

The number of experiments involving increasing doses of repinotan (n = 6) was based on our previous experience, in which a 20-µg/kg dose of repinotan counteracted a morphine-induced ventilatory depression (mean ± SD) to 18 ± 58% of the pretreatment level. With an α set at 0.05, the power was calculated as 0.92 with n = 6 experiments in the double-sided power analysis.

Repinotan and Remifentanil Bolus Injections. Repinotan (10 µg/kg, n = 6; or 20 µg/kg, n = 5, fig. 1B), or NaCl (0.9%) were administered intravenously. Twenty minutes later, remifentanil was injected intravenously as a bolus of 2.5 µg/kg. This dose was found to be the highest possible to avoid hypoxia in preliminary experiments. Because of the brief measurement intervals upon administration of the remifentanil boluses no TFL were taken in this series of experiments.

**Statistical Analysis**

Pretreatment MV, TFL, MAP, HR, and sevoflurane and remifentanil dosing of matched groups were compared with the Mann–Whitney U test. MV during experiments were
calculated as change in percent of pretreatment level (%change) according to the formula: %change = 100 × (MV_{treatment}/MV_{pretreatment}) − 100. This also applies to MAP and HR. TFL were calculated as change in percent of the maximum possible effect (%MPE), as shown in Materials and Methods (see Nociception). MV levels upon repinotan administration were compared with pretreatment levels with Friedman’s repeated measures analysis of variance and Dunn’s multiple comparison test. The same methods were used to compare pretreatment and posttreatment TFL, MAP, and HR. All tests were two-tailed, and P < 0.05 was considered statistically significant. All data were processed with the Chart 4.0 and Scope 4.0 software package (ADInstruments GmbH). Statistical analyses were performed using Prism4® software package for Macintosh (GraphPad Software Inc., San Diego, CA) and IBM® SPSS® Statistics, Version 19 (IBM Deutschland GmbH, Ehningen, Germany).†† The power analysis was done with the Simple Interactive Statistical Analysis (SISA) online software package (Quantitative Skills, Hilversum, The Netherlands).††

**Results**

**Continuous Remifentanil Infusion**

**Spontaneous Breathing.** The median pretreatment MV in the repinotan group was 173 [interquartile range, 149–200] ml/min, 162 [121–171] ml/min in the 8-OH-DPAT group, and 152 [105–201] ml/min in the NaCl (0.9%) group. Sevoflurane concentrations were 3.0 [2.9–3.0] Vol% in the repinotan group, 3.0 [3.0–3.1] Vol% in the 8-OH-DPAT group, and 3.0 [3.0–3.0] Vol% in the NaCl (0.9%) group. Except for a difference in pretreatment MV between the groups did not differ statistically otherwise. Remifentanil depressed MV to −56 [−67 to −52]% in the repinotan group (P = 0.008). Remifentanil counteracted this ventilatory depression in a dose-dependent manner, as indicated by the MV returning almost to pretreatment level (MV, −8 [−26 to 29]% with the moderate dose (10 µg/kg) and to −4 [−8 to 35]% with the high dose (100 µg/kg). MV remained depressed during controls with NaCl (0.9%) (fig. 2). A single dose of remifentanil (10 µg/kg), injected at the end of continuous remifentanil infusion, prevented the return of the TFL to baseline for at least 30 min (fig. 3). This is indicated by the return of the TFL to baseline 45 min after cessation of remifentanil administration, compared with 5 min in the NaCl (0.9%) group. For comparison, remifentanil (10 µg/kg), administered without a preceding remifentanil infusion, did not affect TFL.

**Nociception.** The median pretreatment TFL was 7.5 [6.6–9.1] s; the treatment groups did not differ significantly. During remifentanil infusion, the TFL was always 100%MPE 5 min after onset and throughout remifentanil infusion, meaning that the tail-flick reflex remained completely suppressed (fig. 3). A single dose of remipotan (10 µg/kg), injected at the end of continuous remifentanil infusion, prevented the return of the TFL to baseline for at least 30 min (fig. 3). This is indicated by the return of the TFL to baseline 45 min after cessation of remifentanil administration, compared with 5 min in the NaCl (0.9%) group. For comparison, remipotan (10 µg/kg), administered without a preceding remifentanil infusion, did not affect TFL.

**Remifentanil Bolus Injection**

The median pretreatment MV in the repinotan 10 µg/kg group was 167 [120–207] ml/min, 161 [144–190] ml/min in the repinotan 20 µg/kg group, and 149 [120–190] ml/min in the NaCl 0.9% group. Sevoflurane concentrations were 3.0 Vol% in all groups. There were no statistical significant differences between groups. Figure 4 shows a representative experiment on the prevention of remifentanil-induced ventilatory depression. Figure 5 shows that a remifentanil bolus (2.5 µg/kg) without preceding remifentanil administration depressed spontaneous breathing to −64 [−81 to 56]% (P = 0.031, compared with the pretreatment level). This ventilatory depression was blunted if remipotan (10 µg/kg;
Cardiovascular Effects
Remifentanil induced a depression of both MAP and HR, both if administered continuously (table 1) and also as a bolus injection (table 2). Unlike ventilatory effects, MAP reduction was not alleviated by repinotan, if given subsequent to the opioid (table 1) or if given before (table 2). Note that moderate and high doses of repinotan recovered HR because HR changes were not significantly different from the pretreatment level with the 10 and 100 µg/kg dose. Repinotan, given alone, did not show statistically significant effects on MAP and HR (table 2). There were no deleterious cardiovascular complications.

Discussion
This study found that a moderate dose of repinotan (10 µg/kg), given alone, had no intrinsic antinociceptive effect, but it prolonged opioid-induced antinociception after discontinuation of remifentanil to at least 30 min. Repinotan (10 and 20 µg/kg) significantly blunted the ventilatory depression caused by bolus injections of remifentanil. It was also confirmed that the sustained ventilatory depression caused by continuous infusion of remifentanil was antagonized by moderate and higher doses of repinotan (10 and 100 µg/kg). Repinotan had a mild, yet statistically nonsignificant, tendency to induce tachycardia and hypotension and did not produce serious cardiovascular complications even with the highest dose.

The dose–response curve for repinotan counteracting the remifentanil-induced ventilatory depression aimed at verifying whether stimulatory effects in remifentanil-induced ventilatory depression are comparable with those obtained previously with morphine5 and to identify a moderate dose, sufficient to stimulate spontaneous breathing. An ED50 of 3.1 µg/kg was found in this work, which is in the same range previously found in morphine-induced ventilatory depression.5 In that work, we reported an ED50 of 1.9 ± 0.5 µg/kg, with the maximum effective repinotan dose being 20 µg/kg. Note that the ED50 given here should be compared with caution because the required condition, a stable ventilatory depression, is difficult to control for, and MV levels upon opioid administration were different (MV remifentanil, −61% vs. morphine −72%).

A moderate dose of 10 µg/kg repinotan was confirmed to counteract ventilatory depression sufficiently and not to stimulate spontaneous breathing if given alone. Spontaneous breathing is controlled by the brainstem respiratory network, among which different types of neuron groups are interconnected via γ-aminobutyric acid and glycinergic receptors, and with excitatory input from the ascending reticular acti-
respiratory frequency. This effect is far more pronounced in opioid-induced ventilatory depression. (figs. 4 and 5) but strongly activated spontaneous breathing via 5-HT1A-R stimulation, which eventually leads to a shortening of inspiratory burst suppression and thus increased respiratory frequency. This effect is far more pronounced when spontaneous rhythm pattern is disturbed per se. Opioids do not equally depress respiratory neurons; their net effect is among others an inhibition of the off switch of spinal reflexes, but this remains to be determined. It was also verified that repinotan at moderate doses (10 and 20 µg/kg) before remifentanil bolus injection prevented a ventilatory depression. Repinotan doses higher than 20 µg/kg were not investigated to minimize baseline ventilatory stimulation before the remifentanil bolus. This enabled us to demonstrate that the prevention of remifentanil-induced depression is a specific effect of repinotan within the neuronal respiratory network rather than a simple elevation of baseline MV.

Repinotan has been investigated intravenously for neuroprotection in humans. Initial favorable neurologic outcomes in patients with stroke or traumatic brain injury were later not confirmed by multicenter studies. Recently, the only commercially available 5-HT1A-R agonist for use in humans, buspirone, failed to counteract opioid-induced ventilatory depression in humans and did not display antinociceptive effects in healthy volunteers. Of note, buspirone is only a partial 5-HT1A-R agonist and available only for oral in-
Antinociception of Repinotan and Remifentanil

Table 1. Effects of Repinotan and 8-OH-DPAT during Continuous Remifentanil on MAP and HR

<table>
<thead>
<tr>
<th></th>
<th>MAP (%change)</th>
<th>HR (%change)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median [IQR]</td>
<td>P Value</td>
</tr>
<tr>
<td>Remifentanil (continuous)</td>
<td>-26 [-33 to -21]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>REP 0.1 µg/kg</td>
<td>-24 [-31 to -10]</td>
<td>0.005</td>
</tr>
<tr>
<td>REP 1 µg/kg</td>
<td>-15 [-29 to -10]</td>
<td>0.006</td>
</tr>
<tr>
<td>REP 10 µg/kg</td>
<td>-17 [-29 to -10]</td>
<td>0.005</td>
</tr>
<tr>
<td>REP 100 µg/kg</td>
<td>-18 [-28 to -11]</td>
<td>0.004</td>
</tr>
<tr>
<td>Remifentanin (continuous)</td>
<td>22 [-27 to -20]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>8-OH 0.1 µg/kg</td>
<td>-20 [-24 to -15]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>8-OH 1 µg/kg</td>
<td>-25 [-28 to -16]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>8-OH 10 µg/kg</td>
<td>-23 [-34 to -14]</td>
<td>0.011</td>
</tr>
<tr>
<td>Remifentanin (continuous)</td>
<td>-22 [-31 to -10]</td>
<td>0.013</td>
</tr>
<tr>
<td>NaCl (0.9%) First application</td>
<td>-16 [-26 to -7]</td>
<td>0.013</td>
</tr>
<tr>
<td>NaCl (0.9%) Second application</td>
<td>-12 [-23 to -6]</td>
<td>0.013</td>
</tr>
<tr>
<td>NaCl (0.9%) Third application</td>
<td>-18 [-21 to -5]</td>
<td>0.008</td>
</tr>
<tr>
<td>NaCl (0.9%) Fourth application</td>
<td>-17 [-24 to -8]</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Effects of repinotan (REP), 8-OH-DPAT (8-OH), and NaCl (0.9%) in combination with continuous infusion of remifentanil on mean arterial pressure (MAP) and heart rate (HR). During remifentanil infusion, concomitant application of REP and 8-OH at small doses (0.1 and 1 µg/kg) did not further change MAP or HR. Moderate (10 µg/kg) and high doses (100 µg/kg) of REP returned HR, but not MAP, almost to the pretreatment level. 8-OH-DPAT (100 µg/kg) was not investigated because serious cardiovascular side effects were seen previously. The NaCl 0.9% group indicates sustained depression of MAP and HR throughout continuous remifentanil infusion. MAP and HR are given as median %change of the pretreatment level (interquartile range [IQR]). Statistics, Friedman’s repeated measures analysis of variance with Dunn’s multiple comparison test, compared with pretreatment level.

* HR in two experiments of the 8-OH-DPAT group was unable to be analyzed because of technical difficulties. All other groups had N = 6.

Table 2. Effects of Remifentanil Bolus Injections after Repinotan Administration on MAP and HR

<table>
<thead>
<tr>
<th></th>
<th>MAP (%change)</th>
<th>HR (%change)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median [IQR]</td>
<td>P Value</td>
</tr>
<tr>
<td>REP 10 µg/kg (n = 6)</td>
<td>-11 [-18 to -6]</td>
<td>0.035</td>
</tr>
<tr>
<td>REMI 2.5 µg/kg (bolus)</td>
<td>-27 [-59 to -11]</td>
<td>0.269</td>
</tr>
<tr>
<td>Control (20 min later)</td>
<td>1 [-11 to 3]</td>
<td>0.674</td>
</tr>
<tr>
<td>REP 20 µg/kg (n = 5)</td>
<td>-14 [-29 to -9]</td>
<td>0.053</td>
</tr>
<tr>
<td>REMI 2.5 µg/kg (bolus)</td>
<td>-28 [-34 to 9]</td>
<td>0.099</td>
</tr>
<tr>
<td>Control (20 min later)</td>
<td>7 [-1 to 9]</td>
<td>0.144</td>
</tr>
<tr>
<td>NaCl (0.9%) (n = 6)</td>
<td>-2 [-11 to 3]</td>
<td>0.393</td>
</tr>
<tr>
<td>REMI 2.5 µg/kg (bolus)</td>
<td>-26 [-30 to -12]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Control (20 min later)</td>
<td>3 [-10 to 8]</td>
<td>0.393</td>
</tr>
</tbody>
</table>

Effects of repinotan (REP) and bolus remifentanil (REMI) on mean arterial pressure (MAP) and heart rate (HR). REP (10 and 20 µg/kg) alone slightly depressed MAP but not HR. Subsequent REMI boluses (2.5 µg/kg) depressed HR, but additional MAP changes did not reach statistical significance. If no REP was given before, REMI depressed MAP and HR. The “control” rows give MAP and HR changes 15 min after bolus injections of REMI or NaCl (0.9%). Both MAP and HR returned to pretreatment levels. MAP and HR are given as median %change of pretreatment level (interquartile range [IQR]). Statistics, Friedman’s repeated measures analysis of variance with Dunn’s multiple comparison test, compared with pretreatment level. P < 0.05 was considered statistically significant.
Some limitations of this study warrant comment. First, an acute, specific tolerance to remifentanil has been suggested by several clinical investigators, whereas others have not found such effect. In our study, the remifentanil concentrations and the anesthetic sevoflurane remained constant once they were leveled to achieve a sustained respiratory depression. Remifentanil dosage was targeted to produce a sustaining ventilatory depression, which led to a complete suppression of the tail-flick reflex in every experiment. Thus, a gradual attenuation of remifentanil-induced antinociception by development of an acute opioid tolerance was hardly detectable by the methods used here.

Second, we did not aim at studying doses of repinotan smaller than the one used here because the scope of this study was the effects of the smallest possible dose to stimulate spontaneous breathing. Again, because 5-HT1A-R is variously located within the trajectories of nociceptive processing, they were reported to enhance or suppress polysynaptic nociceptive reflexes, depending on the experimental setup. Thus, with nociceptive models other than the one used here, there may be activation by small doses of 5-HT1A-R-agonists, which may not be overpowered by opioids. This should be by further studied.

Third, we investigated spontaneously breathing rats anesthetized with pentobarbital and sevoflurane. These substances have marked effects on γ-aminobutyric acid receptors, which are also involved in the respiratory network. It is conceivable that the effects of 5-HT1A-R-agonists may be different in nonanesthetized mammals. However, we have reported on the effects of the 5-HT1A-R-agonist 8-OH-DPAT in a perfused, nonanesthetized, brainstem spinal cord preparation and concluded that the stimulatory effect of 5-HT1A-R-agonists is independent from interaction with γ-aminobutyric acid receptors.

Fourth, the experimental setup did not aim at investigating specific serotonergic side effects, such as the serotonergic syndrome. It is characterized by symptoms such as headache, nausea and vomiting, flush, tachycardia, and agitation in humans and may even aggravate in coadministration with 8-OH-DPAT. Therefore, the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. Thus, with nociceptive models other than the one used here, there may be activation by small doses of 5-HT1A-R-agonists, which may not be overpowered by opioids. This should be by further studied.

The 5-HT1A-R-agonist repinotan prevented remifentanil-induced ventilatory depression in spontaneously breathing, anesthetized rats. Although a single dose of repinotan alone (10 μg/kg) did not show intrinsic antinoceptive, it prolonged the opioid-induced antinociception after discontinuation of remifentanil infusion. 5-HT1A-R-agonists should be the subject to additional research regarding their ventilatory and antinociceptive effects.

Conclusions

The 5-HT1A-R-agonist repinotan prevented remifentanil-induced ventilatory depression in spontaneously breathing, anesthetized rats. Although a single dose of repinotan alone (10 μg/kg) did not show intrinsic antinociception, it prolonged the opioid-induced antinociception after discontinuation of remifentanil infusion. 5-HT1A-R-agonists should be the subject to additional research regarding their ventilatory and antinociceptive effects.

References


Anesthesiology 2012; 116:56–64

The authors thank Tanja Schloesser, Scientific Technician, for excellent technical assistance during the experiments, and Sven Zenker, M.D., Resident in Anesthesiology, for thorough statistical advice. Both are affiliated with the Clinic of Anesthesiology and Intensive Care Medicine, Bonn University Hospital, Bonn, Germany.


